Indeed, CYP2W1 is known to be a poor prognostic marker in CRC and expression in metastatic disease is enhanced compared with primary malignant sites.25, 26 Tumour‐specific expression of CYP2W1 infers potential as a putative molecular drug target, able to bioactivate anticancer prodrug candidates at the tumour site (minimizing systemic exposure to active species). Here, CYP2W1 is linked to metastatic neoplasm.